Antifungal prophylaxis
REMISSION
At the time the HOVON-43 trial was performed antifungal prophylaxis was not prescribed to patients. Nowadays, From the observed overall incidence of IA of 21% it becomes clear that antifungal prophylaxis would have been indicated in this group, in particular during remission induction chemotherapy. Only one patient developed IA during post remission chemotherapy. The reported incidence of IA during consolidation chemotherapy is low, around 2–3% [